



Evidence reviews – June 2021

Evidence review

Published: 25 June 2021

www.nice.org.uk

The following documents contain the evidence that was used to develop the 2021 recommendations:

- [Information and support](#)
- [Skin care advice for people with acne vulgaris](#)
- [Dietary interventions for the treatment of acne vulgaris](#)
- [Referral to specialist care](#)
- [Management options for mild to moderate acne – network meta-analyses](#)
- [Management options for mild to moderate acne – pairwise comparisons](#)
- [Management options for moderate to severe acne – network meta-analyses](#)
- [Management options for moderate to severe acne – pairwise comparisons](#)
- [Management options for people with acne vulgaris and polycystic ovary syndrome](#)
- [Management options for refractory acne](#)
- [Maintenance treatment for acne vulgaris](#)
- [Addition of oral corticosteroids to oral isotretinoin for the treatment of severe inflammatory acne vulgaris](#)
- [Intralesional corticosteroids for the treatment of individual acne vulgaris lesions](#)
- [Risk factors for scarring due to acne vulgaris](#)
- [Management of acne vulgaris-associated scarring](#)

Supplements

- [Methods](#)

Mild to moderate acne:

- [Technical Support Unit \(TSU\) network meta-analysis \(NMA\) software code](#)
- [NMA data](#)
- [NMA of efficacy – included and excluded studies](#)
- [NMA, direct and indirect estimates](#)

Moderate to severe acne:

- [TSU NMA software code](#)
- [NMA data](#)
- [NMA of efficacy – included and excluded studies](#)
- [NMA, direct and indirect estimates](#)